FUJIFILM Medical Systems U.S.A., Inc., announced today that its Synapse 5 PACS technology has received FDA 510(k) clearance for sale and distribution in the U.S.
The announcement is the latest for the company’s Synapse product line, which also includes VNA, 3D, RIS, cardiovascular and mobile offerings, FUJIFILM said in a press release.
"As reimbursement continues to move from volume-driven to value-based, radiologists need to boost their efficiency, their productivity and their accuracy. The challenge is to be a speed reader who, despite the high velocity, doesn't miss a single abnormality on a single study," said chief operating officer Johann Fernando, PhD. "Synapse 5 is designed to help our customers keep up with the changes that have already taken place and, more importantly, to help them stay out ahead of what comes next."
The newly released PACS will be available to existing Fujifilm customers through an upgrade to current systems and will utilize a browser-independent desktop experience, allowing organizations to save significant resources due to less desktop management and reduce bandwidth requirements associated with previous PACS products, the company said.
The Synapse 5 will be on display at HIMSS16 in Las Vegas, according to the press release.